

Elsevier Editorial System(tm) for European Journal of Medical Genetics
Manuscript Draft

Manuscript Number:

Title: Phenotype-genotype correlations for clinical variants caused by CYLD mutations

Article Type: Review Article

Keywords: cylindromatosis gene; Brooke-Spiegler syndrome; familial cylindromatosis; familial trichoepitheliomatosis; mutation update

Corresponding Author: Dr. Nikoletta Nagy,

Corresponding Author's Institution:

First Author: Nikoletta Nagy

Order of Authors: Nikoletta Nagy; Katalin Farkas; Lajos Kemény; Márta Széll

Abstract: Brooke-Spiegler syndrome (BSS; OMIM 605041) is an autosomal dominant condition characterized by skin appendageal neoplasms including cylindromas, trichoepitheliomas, and/or spiradenomas. In 1996, the gene locus for BSS was mapped to 16q12-13, and, in 2000, mutations in the cylindromatosis (CYLD) gene were determined to cause BSS, familial cylindromatosis (FC; OMIM 132700) and multiple familial trichoepithelioma type 1 (MFT1; OMIM 601606). The CYLD gene encodes an enzyme with deubiquitinase activity. To date, a total of 95 different diseases-causing mutations have been published for the CYLD gene. A summary of mutations identified in Hungarian patients and a review of previously published mutations are presented in this update. The majority of the sequence changes are frameshift (48%), nonsense (27%), missense (12%) and splice-site (11%) mutations; however, two in-frame deletions have also been reported. Most mutations are located in exons 9-20. Analysis of the identified CYLD gene mutations and the observed BSS, FC and MFT1 clinical phenotypes of the patients revealed significant genotype-phenotype correlations. Elucidation of these genotype-phenotype correlations is critical for the diagnosis of these rare monogenic skin diseases. In addition, characterized correlations may promote the understanding of their mechanisms and may hopefully contribute to the development of future therapeutic modalities.

Dear Dr. Verloes,

R.e. „Phenotype - genotype correlations for clinical variants caused by CYLD mutations” by
Nikoletta Nagy, Katalin Farkas, Lajos Kemény, Márta Széll

It was a pleasure to meet you at the ESHG in Milan.

Here I would like to submit my work as a review to the EJHG.

Thank you very much for considering my work.

Kind Regards,

Nikoletta Nagy

Phenotype–genotype correlations for clinical variants caused by *CYLD* mutations

Nikoletta Nagy^{1,2,3}, Katalin Farkas³, Lajos Kemény^{2,3}, Márta Széll^{1,3}

¹Department of Medical Genetics, University of Szeged, Szeged, HUNGARY

²Department of Dermatology and Allergology, University of Szeged, Szeged, HUNGARY

³Dermatological Research Group of the Hungarian Academy of Sciences, University of Szeged, Szeged, HUNGARY

Corresponding author:

Dr. Nikoletta Nagy, Department of Medical Genetics, University of Szeged

4 Somogyi Béla utca, H-6720 Szeged, HUNGARY

Email: nikoletta.nagy@gmail.com

SUMMARY

1
2
3
4 Brooke-Spiegler syndrome (BSS; OMIM 605041) is an autosomal dominant condition
5 characterized by skin appendageal neoplasms including cylindromas, trichoepitheliomas,
6 and/or spiradenomas. In 1996, the gene locus for BSS was mapped to 16q12-13, and, in 2000,
7 mutations in the *cylindromatosis* (*CYLD*) gene were determined to cause BSS, familial
8 cylindromatosis (FC; OMIM 132700) and multiple familial trichoepithelioma type 1 (MFT1;
9 OMIM 601606). The *CYLD* gene encodes an enzyme with deubiquitinase activity. To date, a
10 total of 95 different diseases-causing mutations have been published for the *CYLD* gene. A
11 summary of mutations identified in Hungarian patients and a review of previously published
12 mutations are presented in this update. The majority of the sequence changes are frameshift
13 (48%), nonsense (27%), missense (12%) and splice-site (11%) mutations; however, two in-
14 frame deletions have also been reported. Most mutations are located in exons 9–20. Analysis
15 of the identified *CYLD* gene mutations and the observed BSS, FC and MFT1 clinical
16 phenotypes of the patients revealed significant genotype–phenotype correlations. Elucidation
17 of these genotype–phenotype correlations is critical for the diagnosis of these rare monogenic
18 skin diseases. In addition, characterized correlations may promote the understanding of their
19 mechanisms and may hopefully contribute to the development of future therapeutic
20 modalities.

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48 **Key words:** cylindromatosis gene, Brooke-Spiegler syndrome, familial cylindromatosis,
49 familial trichoepitheliomatosis, mutation update
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

BACKGROUND

1
2
3
4 Brooke-Spiegler syndrome (BSS, OMIM 605041) is a rare monogenic skin disease
5 (genodermatosis) characterized by the development of a wide variety of benign skin
6
7 appendageal tumors, such as cylindromas, trichoepitheliomas and/or spiradenomas [Brooke,
8
9 1892; Spiegler, 1899]. The first symptoms of BSS are small skin-colored papules, which
10
11 occur in childhood and adolescence [EVANS, 1954; Sima et al., 2010]. These tumors grow
12
13 slowly in size and continue appear throughout the lifetime of the patient [Blake and Toro,
14
15 2009]. Expression of the papules exhibits wide variation among and within affected families
16
17 [Poblete et al., 2002].
18
19

20
21
22 Cylindromas are slowly growing benign tumors that are usually located on the scalp and face.
23
24 Typically, they appear as multiple turban-like protrusions on the scalp, which are also referred
25
26 as turban tumors [Uede et al., 2004]. Cylindromas are histologically characterized by dermal
27
28 nodules of epithelial cells: large cells with abundant cytoplasm occur at the center of the
29
30 tumors, where as small basaloid cells occur at the periphery. The cells are lined by membrane-
31
32 like basement material and arranged in a “jigsaw puzzle” pattern [Lian and Cockerell, 2005].
33
34 Cylindromas express hair keratins [Massoumi et al., 2006].
35
36
37
38

39
40
41 Trichoepitheliomas are small benign skin-colored tumors and are typically present at the
42
43 center of the face, mostly around the nose, periorbitally and in the nasolabial folds [Uede et
44
45 al., 2004]. Histologically, trichoepitheliomas are characterized by basaloid cells with
46
47 peripheral palisades that are arranged in nests or cribriform patterns surrounded by dense
48
49 stroma and fibroblasts [Alsaad et al., 2007].
50
51

52
53 Spiradenomas are purple benign nodular tumors, which are usually located on the trunk or
54
55 limbs [Uede et al., 2004]. Histologically, spiradenomas are composed of large tumor nests
56
57 comprising two types of epithelial cells [Obaidat et al., 2007]. Large light-colored cells with
58
59
60
61
62
63
64
65

1 abundant cytoplasm at the center of the nests are surrounded by small darker cells at the
2 periphery [Obaidat et al., 2007; Michal et al., 1999]. Spiradenomas rarely become malignant
3 but can transform into spiradenocarcinomas [Cooper et al., 1985; Engel et al., 1991; Chou et
4 al., 2004]. Hybrid tumors can also occur, such as spiradenocylindromas, which exhibit the
5 characteristics of both cylindromas and spiradenomas [Kazakov et al., 2005; Kazakov et al.,
6 2008; Pizinger and Michal, 2000].
7

8 BSS is transmitted as an autosomal dominant condition affecting males and females equally
9 [GUGGENHEIM and Schnyder, 1961]. BSS and its phenotypic variants were independently
10 mapped to chromosome 16q12-q13 by several groups [Fenske et al., 2000; Biggs et al., 1995;
11 Biggs et al., 1996; Takahashi et al., 2000]. Within the mapped region, the cylindromatosis
12 gene (*CYLD*) was identified as the causative gene responsible for the development of the
13 disease [Takahashi et al., 2000; Bignell et al., 2000]. The *CYLD* gene (GenBank accession
14 number NM_015247) spans 56 kb and contains 20 exons, the first 3 of which are untranslated,
15 and 19 introns. Of the 17 known splice variants, 13 affect protein coding regions, and the
16 remaining produce non-coding transcripts (<http://ensemble.org>). The tumor suppressing
17 *CYLD* gene encodes an enzyme with deubiquitinase activity. The *CYLD* enzyme post-
18 translationally modifies its target proteins by removing Lys63-linked ubiquitin chains
19 [Kovalenko et al., 2003]. The protein interacts with several members of the NF- κ B signaling
20 pathway, including the TRAF2, TRAF6, NEMO and BCL3 proteins, acting as a negative
21 regulator [Hutti et al., 2009].
22

23 In 2000, the first 21 mutations of the *CYLD* gene were identified in the affected members of
24 21 families with familial cylindromatosis (FC; OMIM 132700), a clinical variant of BSS
25 [Bignell et al., 2000]. Since 2000, several reports have described mutations in the *CYLD* gene
26 in different cases from around the world [Blake and Toro, 2009]. In addition to BSS and FC,
27 mutations of the *CYLD* gene have also been reported in patients with multiple familial
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 trichoepithelioma type 1 (MFT1; OMIM 601606) [Hu et al., 2003]. BSS, FC and MFT1 show
2 overlapping phenotypic features: some BSS patients develop multiple skin appendage tumors
3 including cylindromas, trichoepitheliomas, and spiradenomas, whereas patients with FC
4 develop only cylindromas, and patients with MFT1 develop only trichoepitheliomas (Table I)
5 [Brooke, 1892] [Spiegler, 1899; Ancell, 1842; Fordyce, 1892; Zhang et al., 2004]. BSS, FC
6 and MFT1 were originally described as distinct clinical entities, but due to their overlapping
7 clinical symptoms and their manifestation within the same families, they are now considered
8 as a clinical variants that represent a phenotypic spectrum of a single entity [Lee et al., 2005;
9 Welch et al., 1968; Young et al., 2006; Oranje et al., 2008].

10 To date, a total of 95 mutations have been reported for the *CYLD* gene. Each of the clinical
11 variants is associated with approximately one third of the known mutations: BSS (35%),
12 MFT1 (36%) and FC (41%). Note that some of the mutations (12%) were detected in two or
13 three different clinical variants: the presence of the c.1112C/A p.S371X, c.2272C/T p.R758X
14 and c.2806C/T p.R936X nonsense mutations can lead to the development of all three clinical
15 variants [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011;
16 Lv et al., 2008; Kacerovska et al., 2013; Saggari et al., 2008; Van den Ouweland et al., 2011;
17 Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al.,
18 2013]. Therefore, it has been hypothesized that BSS, FC and MFT1 are not different disease
19 entities, but represent a phenotypic spectrum of the same disease.

20 **SUMMARY OF HUNGARIAN BSS PATIENTS**

21 In Hungary, mutation screening for the *CYLD* gene has been available since 2010. Screening
22 has been performed with direct sequencing of all coding regions and flanking introns of the
23 *CYLD* gene. Once a putative causative variant was identified in a patient, the available,

1 clinically symptom-free family members and unrelated, healthy control individuals were also
2 investigated. To our knowledge, our workgroup is the only one in Hungary that performs
3 genetic screening for BSS, FC and MFT1.
4

5
6
7 We have identified two Hungarian pedigrees with BSS. One family (Pedigree I) is located in
8 Szeged, Hungary; the other (Pedigree II), located in Hungary close to Szekszárd, has
9 Bukovinian (Romania) origin. Two affected individuals in Pedigree I — a father and his
10 daughter — exhibit mild symptoms on their scalp, middle face and trunk [Linos et al., 2011].
11
12

13
14
15
16 Pedigree II contains 21 affected family members from seven generations, all of whom exhibit
17 severe symptoms also located on their scalp, middle face and trunk [Grossmann et al., 2013].
18

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1 and results in different symptom severity as well as the development of different clinical
2 variants [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Saggar et al., 2008;
3
4 Kazakov et al., 2009; Nagy et al., 2013].
5
6
7
8

9 **VARIANTS OF THE *CYLD* GENE**

10
11
12
13
14 A PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) literature search was performed to identify
15 all patients with *CYLD* mutations. In addition, data from Hungarian BSS pedigrees carrying
16
17 *CYLD* mutations have also been included for the present publication. To date, a total of 95
18
19 mutations have been published for the *CYLD* gene, and the individuals carrying these
20
21 mutations present with phenotypic features of BSS, FC and/or MFT1 (Figure 1). Mutations
22
23 are named according to Human Genome Variation Society (HGVS) nomenclature guidelines
24
25 (www.HGVS.org) and numbered with respect to the *CYLD* gene reference sequence
26
27 (ENSG00000083799 corresponding to the *CYLD* gene transcript ENST00000311559).
28
29
30
31
32

33
34 The majority of the *CYLD* mutations (98%) were reported in coding regions. Distribution of
35
36 the mutations within exons is unequal: 99% of the mutations are located within exons 9–20
37
38 (Figure 1). The majority of the sequence changes are frameshift (48%), nonsense (27%),
39
40 missense (12%) or splice-site (11%) mutations; however two in-frame deletions have also
41
42 been reported.
43
44

45
46 Approximately half of the identified *CYLD* mutations (48%) are frameshift mutations arising
47
48 from the insertion or deletion of a small number of nucleotides. The majority of these changes
49
50 lead to the formation of premature stop codons causing truncation and, thus, the dysfunction
51
52 of the *CYLD* protein (Figure 2). Frameshift mutations are also unequally distributed in the
53
54 *CYLD* gene (Figure 3): one third are located within the region spanning exons 5–11 [Bignell
55
56 et al., 2000; Grossmann et al., 2013; Saggar et al., 2008; Nasti et al., 2009; Ying et al., 2012;
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Liang et al., 2008; Zheng et al., 2004], whereas the rest (66%) occur within the region
spanning exons 12–20 [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Lv et
al., 2008] [Saggar et al., 2008; Oiso et al., 2004; Reuven et al., 2013; Chen et al., 2011; Salhi
et al., 2004; Melly et al., 2012; Heinritz et al., 2006]. Exon 17 is a mutational hotspot,
containing 20% of all identified frameshift mutations [Bignell et al., 2000; Bowen et al.,
2005; Grossmann et al., 2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 2004]. Only a
quarter of the frameshift mutations (27%) are recurrent, i.e., having been reported by at least
two studies [Sima et al., 2010; Poblete et al., 2002; Bignell et al., 2000; Bowen et al., 2005;
Grossmann et al., 2013; Saggar et al., 2008; Oiso et al., 2004; Scheinfeld et al., 2003; Hester
et al., 2013]. In general, different frameshift mutations can lead to the development of the
different allelic variants and show phenotypic diversity (Figure 4) [Bignell et al., 2000;
Saggar et al., 2008; Nasti et al., 2009; Ying et al., 2012; Liang et al., 2008; Scheinfeld et al.,
2003; Hester et al., 2013; Scholz et al., 2010].

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
Nonsense mutations causing truncation and, thus, *CYLD* protein dysfunction are also
common, accounting for one quarter (27%) of the *CYLD* mutations identified so far (Figure
2). The distribution of nonsense mutations is also unequal in the *CYLD* gene (Figure 3). One
third of the nonsense mutations occur within the region spanning exons 9–11 [Sima et al.,
2010; Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv
et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011;
Kazakov et al., 2009; Almeida et al., 2008], while the majority (72%) are located within the
region spanning exons 12–20 [Sima et al., 2010; Bignell et al., 2000; Zhang et al., 2004;
Young et al., 2006; Oranje et al., 2008; Bowen et al., 2005; Grossmann et al., 2013; Oiso et
al., 2004; Kazakov et al., 2009; Nagy et al., 2013; Nagy et al., 2012; Zheng et al., 2004; Chen
et al., 2011; Almeida et al., 2008]. This latter region does not seem to contain a further
mutational hotspot. It is of interest to note that 25% of the identified nonsense mutations

1 affect glutamine amino acid residues within the *CYLD* protein, replacing them with stop
2 codons [Sima et al., 2010; Bignell et al., 2000; Grossmann et al., 2013; Zheng et al., 2004;
3
4 Chen et al., 2011; Almeida et al., 2008]. Nearly half of the nonsense mutations (40%) are
5
6 recurrent [Sima et al., 2010; Bignell et al., 2000; Oranje et al., 2008; Bowen et al., 2005;
7
8 Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et
9
10 al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et
11
12 al., 2009; Kazakov et al., 2011; Nagy et al., 2013; Zheng et al., 2004; Chen et al., 2011]. In
13
14 general, nonsense mutations – even the same mutation in different individuals – lead to the
15
16 development of the different clinical variants; thus, nonsense mutations have been associated
17
18 with the highest phenotypic diversity (Figure 4) [Bignell et al., 2000; Bowen et al., 2005;
19
20 Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et
21
22 al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et
23
24 al., 2009; Kazakov et al., 2011; Nagy et al., 2013].

25
26 Missense mutations account for 12% of all mutations identified on the *CYLD* gene (Figure 2).
27
28 The distribution of missense mutations is also unequal on the *CYLD* gene (Figure 3): all are
29
30 located within the region spanning exons 12–20 [Sima et al., 2010; Hu et al., 2003;
31
32 Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et
33
34 al., 2008; Van den Ouweland et al., 2011; Kazakov et al., 2009; Nagy et al., 2012; Zheng et
35
36 al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007]. Only
37
38 a quarter (27%) of these are recurrent mutations [Sima et al., 2010; Hu et al., 2003;
39
40 Grossmann et al., 2013; Saggar et al., 2008; Kazakov et al., 2009]. In general, missense
41
42 mutations of the *CYLD* gene have been associated with less phenotypic diversity than other
43
44 kinds of mutations: three quarters (73%) have been reported in MFT1 only (Figure 4) [Nagy
45
46 et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010;
47
48 Zuo et al., 2007].

1 Splice-site mutations account for 11% of all mutations (Figure 2). The distribution of the
2 splice-site mutations is also unequal (Figure 3): all of them occur within the region spanning
3 exons 10–18 [Bignell et al., 2000; Grossmann et al., 2013; Kacerovska et al., 2013; Van den
4 Ouweland et al., 2011; Kazakov et al., 2011; Nasti et al., 2009; Ying et al., 2012; Liang et al.,
5 2008; Huang et al., 2009; Ly et al., 2004]. Less than a quarter (18%) are recurrent [Bignell et
6 al., 2000; Grossmann et al., 2013; Van den Ouweland et al., 2011; Kazakov et al., 2011]. In
7 general, splice-site mutations can lead to the development of different clinical variants and
8 show phenotypic diversity (Figure 4) [Kacerovska et al., 2013; Van den Ouweland et al.,
9 2011; Nasti et al., 2009; Liang et al., 2008; Huang et al., 2009].

10 In addition, two in-frame deletions have also been reported: these mutations are located within
11 exons 19 and 20. Both of them lead to the development of the FC clinical variant [Van den
12 Ouweland et al., 2011].

13 **ETHNIC VARIATION**

14 Mutations of the *CYLD* gene have been reported among patients with Irish, Japanese, Spanish,
15 German, Algerian, Turkish, Hungarian, Slovakian, Italian, Scandinavian, Taiwanese, Turkish,
16 Canadian and African backgrounds [Bowen et al., 2005; Kacerovska et al., 2013; Sagar et
17 al., 2008; Nagy et al., 2013; Nagy et al., 2012; Nasti et al., 2009; Salhi et al., 2004; Huang et
18 al., 2009; Amaro et al., 2010]. However, the majority of the published mutations are reported
19 for patients from the UK, USA and China [Bignell et al., 2000; Lv et al., 2008; Ying et al.,
20 2012; Liang et al., 2008; Zheng et al., 2004; Chen et al., 2011; Wang et al., 2010; Zuo et al.,
21 2007]. Recurrent mutations have been detected in patients living in geographically distant
22 regions: the c.1112C/A p.S371X nonsense mutation was identified in Irish, African American,
23 Slovakian and Chinese patients [Bowen et al., 2005; Linos et al., 2011; Lv et al., 2008;

1 Kacerovska et al., 2013] and the c.2806C/T p.R936X nonsense mutation was detected in
2 Canadian, American, Anglo-Saxon and Hungarian patients [Bignell et al., 2000; Bowen et al.,
3
4 2005; Nagy et al., 2013]. The appearance in geographically distant patients might suggest that
5
6 these recurrent mutations are located in mutational hotspots of the *CYLD* gene [Nagy et al.,
7
8 2013]. Haplotype analysis of patients carrying the same recurrent mutation indicated a
9
10 common ancestor for some patients [Bignell et al., 2000] and independent mutational events
11
12 for others [Nagy et al., 2013].
13
14

15
16 A comparison of ethnicity and allelic variation revealed geographical differences. The clinical
17
18 phenotype of MFT1 was observed mostly in individuals from China but also in African, Afro-
19
20 American, Taiwanese, Algerian, Turkish, Italian and Spanish patients [Lv et al., 2008;
21
22 Kacerovska et al., 2013; Liang et al., 2008; Zheng et al., 2004; Chen et al., 2011; Wang et al.,
23
24 2010; Zuo et al., 2007]. The majority of patients exhibiting the FC clinical variant were from
25
26 the UK and the USA, but some patients were from Italy and Ireland [Bignell et al., 2000;
27
28 Bowen et al., 2005; Nasti et al., 2009]. Like FC, the majority of patients presenting the BSS
29
30 clinical variant were from the UK and the USA; however, patients from Hungary, Slovakia,
31
32 Italy, Scandinavia, Spain and Canada have also been reported [Bignell et al., 2000; Bowen et
33
34 al., 2005; Kacerovska et al., 2013; Nagy et al., 2013; Nagy et al., 2012; Nasti et al., 2009].
35
36
37
38
39
40
41
42

43 **BIOLOGICAL RELEVANCE**

44
45
46
47
48 The protein encoded by the *CYLD* gene (GenBank NP_056062), consisting of 956 amino
49
50 acids with a molecular weight of approximately 120 kD, exhibits deubiquitinase activity. The
51
52 *CYLD* protein plays a role in the posttranslational modification of several proteins by
53
54 removing lysine 63-linked ubiquitin chains. Lysine 63-linked polyubiquitination affects the
55
56 interactions among proteins by creating specific recognition sites for other proteins. However,
57
58
59
60
61
62
63
64
65

1 the CYLD protein, which primarily deubiquitinates lysine 63-linked chains, can also process
2 lysine 48-linked chains as well [Reiley et al., 2006; Komander et al., 2008]. The known
3
4 interaction partners of the CYLD protein include TNF-receptor-associated factor proteins
5
6 (TRAF2, TRAF6 and TRAF7) and the NEMO protein, a negative regulator of the NF- κ B
7
8 signaling pathway [Haglund and Dikic, 2005]. CYLD is involved in the regulation of several
9
10 biological processes, such as cell proliferation and inflammation [Gao et al., 2008].
11

12 The N-terminal of the CYLD protein can be divided into two regions based on the occurrence
13
14 of the mutations: no mutations have been detected in the region encoded by exons 4 and 5,
15
16 whereas the region encoded by exons 5–11 contains approximately one fifth (18%) of the
17
18 mutations identified to date. The N-terminal of the CYLD protein contains three cytoskeleton-
19
20 associated glycine rich domains (CAP-GLY), at which the CYLD protein connects to
21
22 microtubules [Gao et al., 2008]. The N-terminal of the CYLD protein is highly conserved
23
24 through evolution (Figure 5). Mostly frameshift and nonsense mutations occur in this region,
25
26 as well as the two known splice-site mutations [Sima et al., 2010; Bignell et al., 2000; Bowen
27
28 et al., 2005; Grossmann et al., 2013; Kacerovska et al., 2013; Saggar et al., 2008; Kazakov et
29
30 al., 2009] [Nasti et al., 2009; Liang et al., 2008; Zheng et al., 2004; Almeida et al., 2008; Ly et
31
32 al., 2004]. Most frameshift mutations occur in the first (amino acids 127 to 203) and the third
33
34 (amino acids 472 to 540) CAP-GLY domains, whereas most of the nonsense and splice-site
35
36 mutations occur in the region of the third CAP-GLY domain (Figure 3). Frameshift and
37
38 nonsense mutations occurring in this region have been identified for all clinical variants [Sima
39
40 et al., 2010; Bignell et al., 2000; Bowen et al., 2005; Kacerovska et al., 2013; Saggar et al.,
41
42 2008; Nasti et al., 2009; Liang et al., 2008; Zheng et al., 2004; Almeida et al., 2008]. The
43
44 splice-site mutations of this region resulted in the development of the BSS or MFT1 clinical
45
46 variants [Grossmann et al., 2013; Kazakov et al., 2009; Ly et al., 2004]. Missense mutation
47
48 has not been detected at the N-terminal of the CYLD protein.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 The *CYLD* gene has changed relatively little through evolution: the similarity between the
2 human and mouse genes is 94%, and the homology is especially high at the 3' end of the gene
3
4 (Figure 5). This region of the *CYLD* protein, encoded by exons 12–20, contains the ubiquitin-
5 specific protease domain that is responsible for the deubiquitinase activity of the protein. This
6
7 region contains the majority (82%) of identified *CYLD* mutations, including frameshift (72%),
8
9 nonsense (72%) and splice-site (81%) mutations as well as all known missense mutations
10
11 (Figure 3). Mutations of this region are associated with high phenotypic diversity and can lead
12
13 to the development of any of the three clinical variants of the *CYLD* mutation-caused
14
15 spectrum. Functional studies of the identified mutations suggest that mutations of this region
16
17 may decrease the deubiquitinase activity of the *CYLD* protein [Nagy et al., 2012].
18
19
20
21
22
23
24
25

26 **CLINICAL AND DIAGNOSTIC RELEVANCE**

27
28
29
30
31 With respect to the clinical symptoms, FC and MFT1 represent the two extremes of the
32
33 *CYLD* mutation-caused spectrum, where as BSS falls between these two (Table I). All three
34
35 clinical variants exhibit variable expression among and within affected families; however, the
36
37 most extreme differences in the manifested phenotypes have been reported for BSS [Bowen et
38
39 al., 2005; Zhang et al., 2006; Nagy et al., 2013]. The penetrance is high for all three clinical
40
41 variants and increases with age.
42
43
44

45
46 The majority (82%) of *CYLD* mutations are located between exons 12 and 20, especially in
47
48 and around exons 16 and 17 (16%) (Figure 1). This finding has a significant diagnostic
49
50 relevance, as mutation screening of affected individuals should start by examining this region.
51
52
53 If no mutation is identified in the coding regions and the flanking introns of exons 12–20, the
54
55 screening can be expanded to exons 5–11.
56
57
58
59
60
61
62
63
64
65

1 We suggest using direct sequencing for the screening method, as the mutation detection rate is
2 high, estimated at 84% [Saggar et al., 2008]. With the identification of the causative mutation,
3
4 prenatal as well as preimplantation genetic diagnosis can be offered to affected families,
5
6 which, as symptoms of all clinical variants can be very stigmatizing, can have a meaningful
7
8 impact on family planning [Nagy et al., 2013].
9

10
11 Causative therapy is not currently available for BSS patients. However, recent investigation
12
13 demonstrated that tumors with somatic *CYLD* mutation have impaired tropomyosin kinase
14
15 (TRK) signaling. Treatment with small *TRK* inhibitor molecule, lestaurtinib, can reduce
16
17 colony formation and proliferation of *CYLD* mutant tumor cells [Rajan et al., 2011]. These
18
19 data may have huge clinical significance, since lestaurtinib treatment might be a novel
20
21 therapeutic modality for patients suffering from symptoms caused by germline *CYLD*
22
23 mutations.
24
25
26
27
28
29
30

31 **GENOTYPE-PHENOTYPE CORRELATIONS**

32
33
34
35

36 Genotype–phenotype correlations are difficult to establish, as all types of known *CYLD*
37
38 mutation – frameshift, nonsense, missense and splice-site – lead to the development of each
39
40 clinical variant of the *CYLD* mutation-caused spectrum.
41

42
43 For example, frameshift mutations of the *CYLD* gene have been identified for all clinical
44
45 variants of the *CYLD* mutation-caused spectrum. Interestingly, most frameshift mutations
46
47 occur in the region of exon 17 [Bignell et al., 2000; Bowen et al., 2005; Grossmann et al.,
48
49 2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 2004].
50
51

52
53 In general, nonsense mutations of the *CYLD* gene exhibit the largest phenotypic diversity.
54
55 Some nonsense mutations (i.e., c.1112C/A p.S371X, c.2272C/T p.R758X and c.2806C/T
56
57 p.R936X) have been detected in patients diagnosed with FC, BSS or MFT1 [Bignell et al.,
58
59
60
61
62
63
64
65

1 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008;
2 Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004;
3
4 Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013].
5
6 Presumably, this is due to the fact that nonsense mutations are the most recurrent (40%) type
7
8 of *CYLD* mutation [Sima et al., 2010; Bignell et al., 2000; Oranje et al., 2008; Bowen et al.,
9
10 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013;
11
12 Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006;
13
14 Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 2013; Zheng et al., 2004; Chen et al.,
15
16 2011]. As many recurrent nonsense mutations are due to de novo events, their frequency and
17
18 location indicates mutational hotspots on the *CYLD* gene [Bignell et al., 2000; Nagy et al.,
19
20 2013]. Patients carrying the same nonsense mutation from different mutational events often
21
22 exhibit extreme differences in their clinical manifestations [Nagy et al., 2013]. These
23
24 differences might be the consequences of yet unknown genetic factors that modify the
25
26 development of the phenotype. Nonsense mutations are also responsible for the most variable
27
28 expression within families [Bowen et al., 2005; Zhang et al., 2006; Nagy et al., 2013]. These
29
30 differences might be explained by environmental and/or lifestyle factors. Further studies are
31
32 needed to elucidate putative genetic, environmental or lifestyle factors that are responsible for
33
34 the observed great variation in phenotype.
35
36
37
38
39
40
41
42

43 Missense mutations of the *CYLD* gene are more frequently associated only with MFT1 (73%)
44
45 than the other types of mutations [Sima et al., 2010; Hu et al., 2003; Grossmann et al., 2013;
46
47 Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den
48
49 Ouweland et al., 2011; Kazakov et al., 2009; Nagy et al., 2012; Zheng et al., 2004; Almeida et
50
51 al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007]. Missense mutations also
52
53 lead to the development of milder phenotype [Nagy et al., 2012]. This observation might be
54
55 explained by the fact that missense mutations are distributed differently than the other types
56
57
58
59
60
61
62
63
64
65

1 of mutations: they are located only between exons 12–20 and not at all in the 5' end. In
2 general, missense mutations are associated with low phenotypic diversity, as the majority of
3 missense mutations result in the MFT1 phenotype [Nagy et al., 2012; Zheng et al., 2004;
4 Almeida et al., 2008; Espana et al., 2007; Wang et al., 2010; Zuo et al., 2007]. Moreover, only
5 12% of missense mutations are recurrent [Sima et al., 2010; Hu et al., 2003; Grossmann et al.,
6 2013; Saggar et al., 2008; Kazakov et al., 2009].

7 Splice-site mutations of the *CYLD* gene can lead to the development of any clinical variant of
8 the *CYLD* mutation-caused spectrum, but little is known about their phenotypic significance
9 [Kacerovska et al., 2013; Van den Ouweland et al., 2011; Nasti et al., 2009; Liang et al.,
10 2008; Huang et al., 2009].

11 **FUTURE PROSPECTS**

12 The comparison of *CYLD* gene mutations and the observed clinical variation of the patients
13 have already revealed significant genotype–phenotype correlations: nonsense mutations are
14 associated with the highest phenotypic diversity and recurrence rate, while missense
15 mutations are associated with mild symptoms and are strongly associated with the MFT1
16 phenotype. Future efforts might provide insight into the clinical significance of frameshift and
17 splice-site mutations and further elucidate the mechanism of the different phenotypic variants
18 of the *CYLD* mutation-caused spectrum. We believe that careful investigation of genotype–
19 phenotype correlations are necessary to promote better understanding of the BSS, FC and
20 MFT1 clinical variants and provide insight into the underlying molecular mechanisms.
21 Genetic screening and the identification of disease-causing mutations have already had a
22 significant impact on prenatal and preimplantation genetic diagnosis for family planning.
23 Future genetic studies could also provide a solid basis for the development of novel causative

therapies that will be more specific and effective than the symptomatic treatments currently available for patients with FC, BSS and MFT1. Recent investigation identified lestaurtinib, a small TRK-inhibitor molecule, which might be a promising novel therapeutic modality for patients suffering from symptoms caused by germline *CYLD* mutations.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ACKNOWLEDGMENTS

1
2
3
4 This research was supported by the European Union and the State of Hungary and co-
5 financed by the European Social Fund in the framework of TÁMOP-4.2.4.A/ 2-11/1-2012-
6
7
8
9 0001 “National Excellence Program.” Nikoletta Nagy received financial support from the
10
11
12 Hungarian Scientific Research Fund (OTKA) PD104782 grant.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

- 1
2
3 Almeida S, Maillard C, Itin P, Hohl D, Huber M. Five new CYLD mutations in skin
4 appendage tumors and evidence that aspartic acid 681 in CYLD is essential for
5 deubiquitinase activity. *J Invest Dermatol* 2008;128:587-93.
6
7
8 Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms--part 1: an approach to
9 tumours of the pilosebaceous unit. *J Clin Pathol* 2007;60:129-44.
10
11 Amaro C, Freitas I, Lamarao P, Afonso A, Skrzypczak M, Heinritz W. Multiple
12 trichoepitheliomas--a novel mutation in the CYLD gene. *J Eur Acad Dermatol Venereol*
13 2010;24:844-6.
14
15
16 Ancell H. History of a remarkable case of tumours, developed on the head and face;
17 accompanied with a similar disease in the abdomen. *Med Chir Trans* 1842;25:227-306.
18
19
20 Biggs PJ, Chapman P, Lakhani SR, Burn J, Stratton MR. The cylindromatosis gene (cyld1) on
21 chromosome 16q may be the only tumour suppressor gene involved in the development of
22 cylindromas. *Oncogene* 1996;12:1375-7.
23
24
25 Biggs PJ, Wooster R, Ford D, Chapman P, Mangion J, Quirk Y et al. Familial
26 cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13:
27 evidence for its role as a tumour suppressor gene. *Nat Genet* 1995;11:441-3.
28
29
30 Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R et al. Identification of the
31 familial cylindromatosis tumour-suppressor gene. *Nat Genet* 2000;25:160-5.
32
33
34 Blake PW, Toro JR. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler
35 syndrome: novel insights into the role of deubiquitination in cell signaling. *Hum Mutat*
36 2009;30:1025-36.
37
38
39 Bowen S, Gill M, Lee DA, Fisher G, Geronemus RG, Vazquez ME et al. Mutations in the
40 CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial
41 trichoepithelioma: lack of genotype-phenotype correlation. *J Invest Dermatol*
42 2005;124:919-20.
43
44
45 Brooke HG. Epithelioma adenoides cysticum. *British Journal of Dermatology* 1892;4:269-87.
46
47
48 Chen M, Liu H, Fu X, Yu Y, Yu G, Liu H et al. Mutation analysis of the CYLD gene in two
49 Chinese families with multiple familial Trichoepithelioma. *Australas J Dermatol*
50 2011;52:146-7.
51
52
53 Chou SC, Lin SL, Tseng HH. Malignant eccrine spiradenoma: a case report with pulmonary
54 metastasis. *Pathol Int* 2004;54:208-12.
55
56
57 Cooper PH, Frierson HF, Jr., Morrison AG. Malignant transformation of eccrine spiradenoma.
58 *Arch Dermatol* 1985;121:1445-8.
59
60
61
62 Engel CJ, Meads GE, Joseph NG, Stavrakys W. Eccrine spiradenoma: a report of malignant
63 transformation. *Can J Surg* 1991;34:477-80.
64
65

- 1 Espana A, Garcia-Amigot F, Aguado L, Garcia-Foncillas J. A novel missense mutation in the
2 CYLD gene in a Spanish family with multiple familial trichoepithelioma. *Arch Dermatol*
3 2007;143:1209-10.
- 4 EVANS CD. Turban tumour. *Br J Dermatol* 1954;66:434-43.
- 5
6 Fenske C, Banerjee P, Holden C, Carter N. Brooke-Spiegler syndrome locus assigned to
7 16q12-q13. *J Invest Dermatol* 2000;114:1057-8.
- 8
9
10 Fordyce JA. Multiple benign cystic epithelioma of the skin. *Journal of Cutaneous Diseases*
11 1892;10:459-73.
- 12
13 Gao J, Huo L, Sun X, Liu M, Li D, Dong JT et al. The tumor suppressor CYLD regulates
14 microtubule dynamics and plays a role in cell migration. *J Biol Chem* 2008;283:8802-9.
- 15
16
17 Grossmann P, Vanecek T, Steiner P, Kacerovska D, Spagnolo DV, Cribier B et al. Novel and
18 recurrent germline and somatic mutations in a cohort of 67 patients from 48 families with
19 Brooke-Spiegler syndrome including the phenotypic variant of multiple familial
20 trichoepitheliomas and correlation with the histopathologic findings in 379 biopsy
21 specimens. *Am J Dermatopathol* 2013;35:34-44.
- 22
23
24 GUGGENHEIM W, Schnyder UW. [On the nosology of Spiegler-Brookes tumors].
25 *Dermatologica* 1961;122:274-8.
- 26
27
28 Haglund K, Dikic I. Ubiquitylation and cell signaling. *EMBO J* 2005;24:3353-9.
- 29
30 Heinritz W, Grunewald S, Strenge S, Schutz A, Froster UG, Glander HJ et al. A case of
31 Brooke-Spiegler syndrome with a new mutation in the CYLD gene. *Br J Dermatol*
32 2006;154:992-4.
- 33
34
35 Hester CC, Moscato EE, Kazakov DV, Vanecek T, Moretto JC, Seiff SR. A new
36 Cylindromatosis (CYLD) gene mutation in a case of Brooke-Spiegler syndrome
37 masquerading as basal cell carcinoma of the eyelids. *Ophthal Plast Reconstr Surg*
38 2013;29:e10-e11.
- 39
40
41 Hu G, Onder M, Gill M, Aksakal B, Oztas M, Gurer MA et al. A novel missense mutation in
42 CYLD in a family with Brooke-Spiegler syndrome. *J Invest Dermatol* 2003;121:732-4.
- 43
44
45 Huang TM, Chao SC, Lee JY. A novel splicing mutation of the CYLD gene in a Taiwanese
46 family with multiple familial trichoepithelioma. *Clin Exp Dermatol* 2009;34:77-80.
- 47
48
49 Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM et al. Phosphorylation of the
50 tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell
51 transformation. *Mol Cell* 2009;34:461-72.
- 52
53
54 Kacerovska D, Szep Z, Kollarikova L, Vanecek T, Michal M, Danis D et al. A novel germline
55 mutation in the CYLD gene in a Slovak patient with Brooke-Spiegler syndrome. *Cesk*
56 *Patol* 2013;49:89-92.
- 57
58
59 Kazakov DV, Magro G, Kutzner H, Spagnolo DV, Yang Y, Zaspas O et al. Spiradenoma and
60 spiradenocylindroma with an adenomatous or atypical adenomatous component: a
61 clinicopathological study of 6 cases. *Am J Dermatopathol* 2008;30:436-41.
- 62
63
64
65

- 1 Kazakov DV, Soukup R, Mukensnabl P, Boudova L, Michal M. Brooke-Spiegler syndrome:
2 report of a case with combined lesions containing cylindromatous, spiradenomatous,
3 trichoblastomatous, and sebaceous differentiation. *Am J Dermatopathol* 2005;27:27-33.
- 4 Kazakov DV, Thoma-Uszynski S, Vanecek T, Kacerovska D, Grossmann P, Michal M. A
5 case of Brooke-Spiegler syndrome with a novel germline deep intronic mutation in the
6 CYLD gene leading to intronic exonization, diverse somatic mutations, and unusual
7 histology. *Am J Dermatopathol* 2009;31:664-73.
- 8
9
10 Kazakov DV, Vanecek T, Zelger B, Carlson JA, Spagnolo DV, Schaller J et al. Multiple
11 (familial) trichoepitheliomas: a clinicopathological and molecular biological study,
12 including CYLD and PTCH gene analysis, of a series of 16 patients. *Am J Dermatopathol*
13 2011;33:251-65.
- 14
15
16 Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A et al. The structure of the
17 CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B
18 box module. *Mol Cell* 2008;29:451-64.
- 19
20
21 Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour
22 suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. *Nature*
23 2003;424:801-5.
- 24
25
26 Lee DA, Grossman ME, Schneiderman P, Celebi JT. Genetics of skin appendage neoplasms
27 and related syndromes. *J Med Genet* 2005;42:811-9.
- 28
29 Lian F, Cockerell CJ. Cutaneous appendage tumors: familial cylindromatosis and associated
30 tumors update. *Adv Dermatol* 2005;21:217-34.
- 31
32
33 Liang YH, Sun CS, Ye XY, Zhang W, Yang S, Zhang XJ. Novel substitution and frameshift
34 mutations of CYLD in two Chinese families with multiple familial trichoepithelioma. *Br J*
35 *Dermatol* 2008;158:1156-8.
- 36
37
38 Linos K, Schwartz J, Kazakov DV, Vanecek T, Carlson JA. Recurrent CYLD nonsense
39 mutation associated with a severe, disfiguring phenotype in an African American family
40 with multiple familial trichoepithelioma. *Am J Dermatopathol* 2011;33:640-2.
- 41
42
43 Lv HL, Huang YJ, Zhou D, Du YF, Zhao XY, Liang YH et al. A novel missense mutation of
44 CYLD gene in a Chinese family with multiple familial trichoepithelioma. *J Dermatol Sci*
45 2008;50:143-6.
- 46
47
48 Ly H, Black MM, Robson A. Case of the Brooke-Spiegler syndrome. *Australas J Dermatol*
49 2004;45:220-2.
- 50
51
52 Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell
53 proliferation by blocking Bcl-3-dependent NF-kappaB signaling. *Cell* 2006;125:665-77.
- 54
55
56 Melly L, Lawton G, Rajan N. Basal cell carcinoma arising in association with
57 trichoepithelioma in a case of Brooke-Spiegler syndrome with a novel genetic mutation in
58 CYLD. *J Cutan Pathol* 2012;39:977-8.
- 59
60
61
62
63
64
65

- 1 Michal M, Lamovec J, Mukensnabl P, Pizinger K. Spiradenocylindromas of the skin: tumors
2 with morphological features of spiradenoma and cylindroma in the same lesion: report of
3 12 cases. *Pathol Int* 1999;49:419-25.
- 4 Nagy N, Farkas K, Kinyo A, Nemeth IB, Kis E, Varga J et al. A novel missense mutation of
5 the CYLD gene identified in a Hungarian family with Brooke-Spiegler syndrome. *Exp*
6 *Dermatol* 2012;21:967-9.
- 7 Nagy N, Rajan N, Farkas K, Kinyo A, Kemeny L, Szell M. A mutational hotspot in CYLD
8 causing cylindromas: a comparison of phenotypes arising in different genetic backgrounds.
9 *Acta Derm Venereol* 2013;93:743-5.
- 10 Nasti S, Pastorino L, Bruno W, Gargiulo S, Battistuzzi L, Zavattaro E et al. Five novel
11 germline function-impairing mutations of CYLD in Italian patients with multiple
12 cylindromas. *Clin Genet* 2009;76:481-5.
- 13 Obaidat NA, Alsaad KO, Ghazarian D. Skin adnexal neoplasms--part 2: an approach to
14 tumours of cutaneous sweat glands. *J Clin Pathol* 2007;60:145-59.
- 15 Oiso N, Mizuno N, Fukai K, Nakagawa K, Ishii M. Mild phenotype of familial
16 cylindromatosis associated with an R758X nonsense mutation in the CYLD tumour
17 suppressor gene. *Br J Dermatol* 2004;151:1084-6.
- 18 Oranje AP, Halley D, Den Hollander JC, Teepe RG, van de GR, van Den OA et al. Multiple
19 familial trichoepithelioma and familial cylindroma: one cause! *J Eur Acad Dermatol*
20 *Venereol* 2008;22:1395-6.
- 21 Pizinger K, Michal M. Malignant cylindroma in Brooke-Spiegler syndrome. *Dermatology*
22 2000;201:255-7.
- 23 Poblete GP, Eggermann T, Holler D, Jugert FK, Beermann T, Grussendorf-Conen EI et al.
24 Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor
25 suppressor gene CYLD underlies different tumors of skin appendages. *J Invest Dermatol*
26 2002;119:527-31.
- 27 Rajan N, Elliott R, Clewes O, MacKay A, Reis-Filho JS, Burn J et al. Dysregulated TRK
28 signalling is a therapeutic target in CYLD defective tumours. *Oncogene* 2011;30:4243-60.
- 29 Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC et al. Regulation of T
30 cell development by the deubiquitinating enzyme CYLD. *Nat Immunol* 2006;7:411-7.
- 31 Reuven B, Margarita I, Dov H, Ziad K. Multiple trichoepitheliomas associated with a novel
32 heterozygous mutation in the CYLD gene as an adjunct to the histopathological diagnosis.
33 *Am J Dermatopathol* 2013;35:445-7.
- 34 Saggari S, Chernoff KA, Lodha S, Horev L, Kohl S, Honjo RS et al. CYLD mutations in
35 familial skin appendage tumours. *J Med Genet* 2008;45:298-302.
- 36 Salhi A, Bornholdt D, Oeffner F, Malik S, Heid E, Happle R et al. Multiple familial
37 trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene.
38 *Cancer Res* 2004;64:5113-7.

- 1 Scheinfeld N, Hu G, Gill M, Austin C, Celebi JT. Identification of a recurrent mutation in the
2 CYLD gene in Brooke-Spiegler syndrome. *Clin Exp Dermatol* 2003;28:539-41.
- 3 Scholz IM, Numann A, Froster UG, Helmbold P, Enk AH, Naher H. New mutation in the
4 CYLD gene within a family with Brooke-Spiegler syndrome. *J Dtsch Dermatol Ges*
5 2010;8:99-101.
- 6
7
8 Sima R, Vanecek T, Kacerovska D, Trubac P, Cribier B, Rutten A et al. Brooke-Spiegler
9 syndrome: report of 10 patients from 8 families with novel germline mutations: evidence of
10 diverse somatic mutations in the same patient regardless of tumor type. *Diagn Mol Pathol*
11 2010;19:83-91.
- 12
13
14 Spiegler E. Über Endotheliome der Haut. *Arch Dermatol Syphilol* 1899;50:163-76.
- 15
16 Takahashi M, Rapley E, Biggs PJ, Lakhani SR, Cooke D, Hansen J et al. Linkage and LOH
17 studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and
18 refine the CYLD locus on chromosome 16q12-q13. *Hum Genet* 2000;106:58-65.
- 19
20
21 Uede K, Yamamoto Y, Furukawa F. Brooke-Spiegler syndrome associated with cylindroma,
22 trichoepithelioma, spiradenoma, and syringoma. *J Dermatol* 2004;31:32-8.
- 23
24
25 Van den Ouweland AM, Elfferich P, Lamping R, van de GR, Veghel-Plandsoen MM,
26 Franken SM et al. Identification of a large rearrangement in CYLD as a cause of familial
27 cylindromatosis. *Fam Cancer* 2011;10:127-32.
- 28
29 Wang FX, Yang LJ, Li M, Zhang SL, Zhu XH. A novel missense mutation of CYLD gene in
30 a Chinese family with multiple familial trichoepithelioma. *Arch Dermatol Res*
31 2010;302:67-70.
- 32
33
34 Welch JP, Wells RS, Kerr CB. Ansell-Spiegler cylindromas (turban tumours) and Brooke-
35 Fordyce Trichoepitheliomas: evidence for a single genetic entity. *J Med Genet* 1968;5:29-
36 35.
- 37
38
39 Ying ZX, Ma HQ, Liu Y, Xiao SX, Wang YX, Wang GX. A novel mutation of CYLD in a
40 Chinese family with multiple familial trichoepithelioma. *J Eur Acad Dermatol Venereol*
41 2012;26:1420-3.
- 42
43
44 Young AL, Kellermayer R, Szigeti R, Teszas A, Azmi S, Celebi JT. CYLD mutations
45 underlie Brooke-Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma
46 syndromes. *Clin Genet* 2006;70:246-9.
- 47
48
49 Zhang G, Huang Y, Yan K, Li W, Fan X, Liang Y et al. Diverse phenotype of Brooke-
50 Spiegler syndrome associated with a nonsense mutation in the CYLD tumor suppressor
51 gene. *Exp Dermatol* 2006;15:966-70.
- 52
53
54 Zhang XJ, Liang YH, He PP, Yang S, Wang HY, Chen JJ et al. Identification of the
55 cylindromatosis tumor-suppressor gene responsible for multiple familial trichoepithelioma.
56 *J Invest Dermatol* 2004;122:658-64.
- 57
58
59 Zheng G, Hu L, Huang W, Chen K, Zhang X, Yang S et al. CYLD mutation causes multiple
60 familial trichoepithelioma in three Chinese families. *Hum Mutat* 2004;23:400.
- 61
62
63
64
65

Zuo YG, Xu Y, Wang B, Liu YH, Qu T, Fang K et al. A novel mutation of CYLD in a Chinese family with multiple familial trichoepithelioma and no CYLD protein expression in the tumour tissue. *Br J Dermatol* 2007;157:818-21.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FIGURE LEGENDS

1
2
3
4
5 **Figure 1.** *CYLD* gene mutations identified to date.

6
7 **Figure 2.** Frequency of mutation types reported for patients harboring germline *CYLD*
8
9 mutations.

10
11 **Figure 3.** Distribution of mutations in the *CYLD* protein.

12
13 **Figure 4.** Mutation types and phenotypic diversity.

14
15
16
17 **Figure 5.** Conservation of *CYLD* protein sequences throughout evolution. Asterisks indicate
18
19 amino acids that are identical for all analyzed species.

20
21
22
23
24 **Table 1.** Allelic variants of the *CYLD* mutation-caused spectrum.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1
[Click here to download high resolution image](#)




Figure 2
[Click here to download high resolution image](#)




Figure 3
[Click here to download high resolution image](#)




Figure 4
[Click here to download high resolution image](#)






Figure 5
[Click here to download high resolution image](#)

<p>Homo sapiens HSSGLMSQEKVTSFYWEKRIFFYLLLQECVTDKQTKLLKVPKSSIGQYQDRS-VQREK Mus musculus HSSGLMSQEKVTSFYWEKRIFFYLLLQECVTDKQTKLLKVPKSSIGQYQDRS-VQREK Gallus gallus HSSGLMSQEKVTSFYWEKRIFFYLLLQECVTDKQTKLLKVPKSSIGQYQDRS-VQREK Danio rerio HSSGLMSQEKVTSFYWEKRIFFYLLLQECVTDKQTKLLKVPKSSIGQYQDRS-VQREK *** ** **</p>	<p>Homo sapiens IFSARGKQKQIGLKIQLQPHAVLQVDEKDVVEINEKFTTELLLAITNCEERKSLFKNRRL Mus musculus VFSYKQKQKQIGLKIQLQPHAVLQVDEKDVVEINEKFTTELLLAITNCEERKSLFKNRRL Gallus gallus NIFPKGKRLQIGLKIQLQPHAVLQVDEKDVVEINEKFTTELLLAITNCEERKSLFKNRRL Danio rerio IFSARGKQKQIGLKIQLQPHAVLQVDEKDVVEINEKFTTELLLAITNCEERKSLFKNRRL </p>	<p>Homo sapiens SEGLQIDVQCFVRYQLASGEEKFPGVVFPGFLAKRVTGQIFPGVELLEEGKQGFQDQ Mus musculus SEGLQIDVQCFVRYQLASGEEKFPGVVFPGFLAKRVTGQIFPGVELLEEGKQGFQDQ Gallus gallus TNGIQIDIGSFVRYQLASGEEKFPGVVFPGFLAKRVTGQIFPGVELLEEGKQGFQDQ Danio rerio DRANDINQSKVRYQLASGEEKFPGVVFPGFLAKRVTGQIFPGVELLEEGKQGFQDQ </p>	<p>Homo sapiens VYQGRQLPQDDEQGVFVALDKLELIEDDDTALESVYAGPGD-TMQLVPLPLEINSRVSL Mus musculus VYQGRQLPQDDEQGVFVALDKLELIEDDDTALESVYAGPGD-TMQLVPLPLEINSRVSL Gallus gallus QYQGRQLPQDDEQGVFVALDKLELIEDDDTALESVYAGPGD-TMQLVPLPLEINSRVSL Danio rerio VYQGRQLPQDDEQGVFVALDKLELIEDDDTALESVYAGPGD-TMQLVPLPLEINSRVSL *** ** **</p>	<p>Homo sapiens KVGSTIESQTVIFCDVLPKESLQYVGVGMINPIGWDGDFDGAQLCSFASVESTILLK Mus musculus KVGSTIESQTVIFCDVLPKESLQYVGVGMINPIGWDGDFDGAQLCSFASVESTILLK Gallus gallus KIGESIEYQTVIFCDVLPKESLQYVGVGMINPIGWDGDFDGAQLCSFASVESTILLK Danio rerio QTRSPERQTVIFCDVLPKESLQYVGVGMINPIGWDGDFDGAQLCSFASVESTILLK </p>	<p>Homo sapiens INDIIIPALSESQTVQERAPFKLAFMRGVDGKSSSSNPKPKATGSTSDPGSNRSELYTL Mus musculus INDIIIPALSESQTVQERAPFKLAFMRGVDGKSSSSNPKPKATGSTSDPGSNRSELYTL Gallus gallus INDVIP---ETVQDRAPFKLAFMRGVDGKSSSSNPKPKATGSTSDPGSNRSELYTL Danio rerio INDVMP---EYDQDQRLPK-VFACRQGRK-PVSGKPKKSLGLQFGSRKSEFYTL </p>	<p>Homo sapiens NGSVDQSQKSNNTMYIDEVAEDPAKSLTETSDFD-RSDFPQFPFNSLTTENRPH Mus musculus NGSVDQSQKSNNTMYIDEVAEDPAKSLTETSDFD-RSDFPQFPFNSLTTENRPH Gallus gallus NGSVDQSQKSNNTMYIDEVAEDPAKSLTETSDFD-RSDFPQFPFNSLTTENRPH Danio rerio NGSVDQSQKSNNTMYIDEVAEDPAKSLTETSDFD-RSDFPQFPFNSLTTENRPH ***** ** **</p>	<p>Homo sapiens AVEKENPFFYGVIRNIGQYFGINEVLQGLELEDECAQCTDGTFRGTRVFTCALJKALPVK Mus musculus AVEKENPFFYGVIRNIGQYFGINEVLQGLELEDECAQCTDGTFRGTRVFTCALJKALPVK Gallus gallus AVEKENPFFYGVIRNIGQYFGINEVLQGLELEDECAQCTDGTFRGTRVFTCALJKALPVK Danio rerio VEVEKENPFFYGVIRNIGQYFGINEVLQGLELEDECAQCTDGTFRGTRVFTCALJKALPVK </p>	<p>Homo sapiens LEKCRPDRSFPASLQPVSNQIERCNSLAFGGYLSVEVEENTFPFMEKEGLEIMIGKKGQIQ Mus musculus LEKCRPDRSFPASLQPVSNQIERCNSLAFGGYLSVEVEENTFPFMEKEGLEIMIGKKGQIQ Gallus gallus LEKCRPDRSFPASLQPVSNQIERCNSLAFGGYLSVEVEENTFPFMEKEGLEIMIGKKGQIQ Danio rerio LEKCRPDRSFPASLQPVSNQIERCNSLAFGGYLSVEVEENTFPFMEKEGLEIMIGKKGQIQ </p>	<p>Homo sapiens GHYNSCYLDSTLFCFLFAPSSALDVLVLLRPFKNDIKEYYSETQELLATEIVNPLRIYGVV Mus musculus GHYNSCYLDSTLFCFLFAPSSALDVLVLLRPFKNDIKEYYSETQELLATEIVNPLRIYGVV Gallus gallus GHYNSCYLDSTLFCFLFAPSSALDVLVLLRPFKNDIKEYYSETQELLATEIVNPLRIYGVV Danio rerio GHYNSCYLDSTLFCFLFAPSSALDVLVLLRPFKNDIKEYYSETQELLATEIVNPLRIYGVV </p>	<p>Homo sapiens ATKIMKLRKILKVEAASGFTSEKDPSEFLMILFPHILRVEPLLRKISAGQKVVQCYFY Mus musculus ATKIMKLRKILKVEAASGFTSEKDPSEFLMILFPHILRVEPLLRKISAGQKVVQCYFY Gallus gallus ATKIMKLRKILKVEAASGFTSEKDPSEFLMILFPHILRVEPLLRKISAGQKVVQCYFY Danio rerio ATKIMKLRKILKVEAASGFTSEKDPSEFLMILFPHILRVEPLLRKISAGQKVVQCYFY </p>	<p>Homo sapiens QIFMDEKQKVVPTIQQLLEWDFINSLKFAFAFSCLIICNFRFGKDFKLFKIFPSLEL Mus musculus QIFMDEKQKVVPTIQQLLEWDFINSLKFAFAFSCLIICNFRFGKDFKLFKIFPSLEL Gallus gallus QIFMDEKQKVVPTIQQLLEWDFINSLKFAFAFSCLIICNFRFGKDFKLFKIFPSLEL Danio rerio QIFMDEKQKVVPTIQQLLEWDFINSLKFAFAFSCLIICNFRFGKDFKLFKIFPSLEL </p>	<p>Homo sapiens NITDLEDTPRQCRIOGGLANYPECRECYDSDI SAGKIQFCCKTCNTQVHLHFRALNSY Mus musculus NITDLEDTPRQCRIOGGLANYPECRECYDSDI SAGKIQFCCKTCNTQVHLHFRALNSY Gallus gallus NITDLEDTPRQCRIOGGLANYPECRECYDSDI SAGKIQFCCKTCNTQVHLHFRALNSY Danio rerio NITDLEDTPRQCRIOGGLANYPECRECYDSDI SAGKIQFCCKTCNTQVHLHFRALNSY </p>	<p>Homo sapiens NPVSLPKDLFDWAGNRCIPQDMEFLAVLCIETSHYVAFVKYGRDGSAMLFEDNADRD Mus musculus NPVSLPKDLFDWAGNRCIPQDMEFLAVLCIETSHYVAFVKYGRDGSAMLFEDNADRD Gallus gallus NPVSLPKDLFDWAGNRCIPQDMEFLAVLCIETSHYVAFVKYGRDGSAMLFEDNADRD Danio rerio NPVSLPKDLFDWAGNRCIPQDMEFLAVLCIETSHYVAFVKYGRDGSAMLFEDNADRD </p>	<p>Homo sapiens GQNGNFIQVTFCEVGEYLNKSLDLSLDRKIQGAKRLLCDAVMCHYQSPMISLYK Mus musculus GQNGNFIQVTFCEVGEYLNKSLDLSLDRKIQGAKRLLCDAVMCHYQSPMISLYK Gallus gallus GQNGNFIQVTFCEVGEYLNKSLDLSLDRKIQGAKRLLCDAVMCHYQSPMISLYK Danio rerio GQNGNFIQVTFCEVGEYLNKSLDLSLDRKIQGAKRLLCDAVMCHYQSPMISLYK </p>
--	--	---	--	---	--	--	---	--	--	--	--	--	--	--

 Cytoskeleton associated glycine rich domain
 Ubiquitin specific protease domain

Ensembl ID:
Homo sapiens ENSG0000083799 Gallus gallus ENSGALT00000016123
Mus musculus ENSMUSG00000036712 Danio rerio ENSDARG00000060058

Table 1

	Familial cylindromatosis (FC)	Brooke-Spiegler syndrome (BSS)	Multiple familial trichoepithelioma type 1 (MFT1)
OMIM ID	132700	605041	601606
Clinical symptoms	Predominantly cylindromas	Cylindromas, trichoepitheliomas, spiradenomas	Predominantly trichoepitheliomas
<i>CYLD</i> mutations	Any type of mutation	Any type of mutation	Any type of mutation, mostly missense